Autolus

Q3 2025 Financial Results and Business Updates

November 12, 2025

For Investor communication only. Not for use in product promotion. Not for further distribution.

Autolus.com

Disclaimer

These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to: statements regarding Autolus’ development and commercialization of its product candidates; Autolus' manufacturing, sales and marketing plans for AUCATZYL, including expectations regarding the commercial launch in the United States and the ability to reach patients in a timely manner; the amount and timing of milestone payments under Autolus' collaboration and license agreements; and future development plans of obe-cel, including the timing or likelihood of expansion into additional markets or geographies and related regulatory approvals. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: Autolus' ability to maintain regulatory approval of AUCATZYL; its ability to execute its commercialization strategy for AUCATZYL; its ability to develop, manufacture and commercialize its other product candidates and the timing or likelihood of expansion of AUCATZYL into additional markets or geographies; Autolus' ability to maintain a commercial infrastructure and to successfully launch, market and sell AUCATZYL; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; the labelling for AUCATZYL/obe-cel in any future indication or patient population, if approved; the potential for payors to delay, limit or deny coverage for AUCATZYL; Autolus' ability to obtain, maintain and enforce intellectual property protection for AUCATZYL or any product candidates it is developing; the results of clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; and possible safety and efficacy concerns. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus’ actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Autolus' Annual Report on Form 10-K filed with the Securities and Exchange Commission, or the SEC, on March 20, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the Securities and Exchange Commission. All information in this presentation is as of the date of the presentation, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this presentation.

Agenda

- Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications
- Operational Highlights: Dr. Christian Itin, CEO
- Financial Results: Rob Dolski, CFO
- Upcoming Milestones and Conclusion: Dr. Christian Itin, CEO
- Q&A: Dr. Christian Itin and Rob Dolski

Building value with obe-cel

Launch → **Optimize** → **Expand**

Strong execution in r/r B-ALL:

- ✓ Market leadership
- ✓ Broad market access / coverage
- ✓ Reliable product delivery
- ✓ Significant opportunity to grow CAR T market in adult B-ALL
- ✓ Physician interest in ISTs in 1L ALL

Leveraging investments:

- Evolution of team to support next phase of commercial growth
- Business process efficiencies targeting margin improvement

Potential “pipeline in a product" new indications:

- Pediatric ALL – Potential pivotal study
- Lupus nephritis – Potential pivotal study
- Multiple sclerosis – Phase 1 study

Drive market share in ALL – Improve margins – Expand beyond ALL

Expect strong first year of U.S. AUCATZYL® launch

AUCATZYL Net Product Sales

Q3 2025: $21.1 million

Deferred Revenue:
$7.6 million

Nine Months Ended September 30, 2025:
$51.0 million

Executing on Product Delivery



- 60 authorized treatment centers
- Manufacturing success rate >90%
- Attained patient access for >90% of U.S. covered lives ahead of plan

Significant opportunity to increase penetration & grow the CAR T market

CAR T market share in relapsed/refractory disease in 2024: ~15%[1]



Breadth of coverage with existing authorized centers reaches majority of target patient population

Positions us to increase depth of usage within existing networks

Physician real world experience with the product will drive uptake

[1]Source: Komodo claims data

Building value with obe-cel

Launch → **Optimize** → **Expand**

Strong execution in r/r B-ALL:

- ✓ Market leadership
- ✓ Broad market access / coverage
- ✓ Reliable product delivery
- ✓ Significant opportunity to grow CAR T market in adult B-ALL
- ✓ Physician interest in ISTs in 1L ALL

Leveraging investments:

- Evolution of team to support next phase of commercial growth
- Business process efficiencies targeting margin improvement

Potential “pipeline in a product" new indications:

- Pediatric ALL – Potential pivotal study
- Lupus nephritis – Potential pivotal study
- Multiple sclerosis – Phase 1 study

Drive market share in ALL – Improve margins – Expand beyond ALL

Evolution of leadership to support next phase of commercial growth

Focus on margin improvement, facilitating access and expanding obe-cel opportunity

Miranda Neville
Chief Technology Officer

Cintia Piccina
U.S. Chief Commercial Officer and Country GM

Patrick McIlvenny
SVP Finance & Chief Accounting Officer

New team members bring breadth of leadership experience with a focus on market growth, strategic planning and operational excellence

Initiatives to drive efficiencies and cost savings

Streamline – Optimize – Innovate

Foundation is a strong launch performance with highly reliable product supply

Key initiatives

Streamline processes	Optimize	Innovate
Simplify	Automation	Manufacturing & Market access

Building value with obe-cel

Launch → **Optimize** → **Expand**

Strong execution in r/r B-ALL:

- ✓ Market leadership
- ✓ Broad market access / coverage
- ✓ Reliable product delivery
- ✓ Significant opportunity to grow CAR T market in adult B-ALL
- ✓ Physician interest in ISTs in 1L ALL

Leveraging investments:

- Evolution of team to support next phase of commercial growth
- Business process efficiencies targeting margin improvement

Potential “pipeline in a product" new indications:

- Pediatric ALL – Potential pivotal study
- Lupus nephritis – Potential pivotal study
- Multiple sclerosis – Phase 1 study

Drive market share in ALL – Improve margins – Expand beyond ALL

Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL

Indication	Trial	Status
Pediatric r/r B-ALL	CATULUS Phase 1/2	Initial data at ASH 2025; RMAT designation received
Systemic Lupus (SLE)	CARSLYLE Phase 1	Initial data at ACR 2025, ASH 2025
Lupus Nephritis (LN)	LUMINA Phase 2	First patient expected to be dosed by YE 2025
Progressive Multiple Sclerosis	BOBCAT Phase 1	First patient dosed October 2025

Supported by external opportunities:

- Investigator-sponsored trials in earlier line settings of acute lymphoblastic leukemia (ALL)
- Real world experience obe-cel data being generated by ROCCA Consortium in r/r aALL

Oncology Autoimmune

Obe-cel shows promise as a new approach for SLE/LN

50 million cell dose selected as recommended Phase 2 dose

Patient population: Patients (50M cell cohort n=6) were significantly impaired with their kidney function and had across the board some of the highest SLEDAI-2K scores included in current SLE studies.

Efficacy: Minimum follow up of 6 months

- Achievement of DORIS in 83.3% (n=5/6) of patients
- Achievement of CRR in 50% (n=3/6 pts) of patients
- No evidence of new disease activity at up to month 14 of follow-up, no lupus directed therapy

Safety: Obe-cel was generally well tolerated in all patients with no ICANS, no high-grade CRS and no DLTs

PK/Biomarkers: All patients showed deep B-cell depletion shortly after infusion, which was subsequently followed by a predominance of naïve B-cell reconstitution, suggesting an obe-cel-driven immune reset.

Next Steps: Phase 1 enrollment is ongoing in adolescents (aged 12–17 years) at the same dose and in adults at a higher dose. Data support progression into a Phase 2 lupus nephritis trial

Leandro et al., American College of Rheumatology Conference 2025 Abstract #2458

Obe-cel is well tolerated with no DLTs, ICANS or high-grade CRS

50 million cell dose patient cohort (n=6)

Key Safety Findings

- No DLTs were observed following obe-cel infusion
- No patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS)
- Only Grade 1 CRS (fever ≥38°C) was observed in 3/6 patients
- All patients had Grade ≥3 neutropenia after lymphodepletion which resolved by Day 22
- All infections were manageable; no Grade ≥4 infections occurred
- Transient hypertension was observed in five patients (n=3 had pre-existing hypertension)

	Infused patients (N=6)	
	Any grade, n (%)	Grade ≥3, n (%)
Any treatment-emergent adverse event	6 (100)	6 (100)
Neutropenia	6 (100)	6 (100)
Infection	6 (100)	2 (33.3)
Hypertension	5 (83.3)	4 (66.7)
Anemia	4 (66.7)	3 (50.0)
Cytokine release syndrome	3 (50.0)	0
Febrile neutropenia	2 (33.3)	2 (33.3)
Thrombocytopenia	1 (16.7)	1 (16.7)
Immune effector cell-associated neurotoxicity syndrome	0	0

Leandro et al., American College of Rheumatology Conference 2025 Abstract #2458

CRS, cytokine release syndrome; DLT, dose-limiting toxicities; ICANS, immune effector cell-associated neurotoxicity syndrome.

All patients achieved significant and sustained SLEDAI-2K reductions (50M cell dose cohort, n=6)



- All non-renal descriptors resolved by month four
- Median SLEDAI-2K reduction of 14 points (range 3-18) at month six
- Three patients (50%) are in ongoing complete renal response (CRR) with onset at 1 month

*Subsequent timepoint in normal range.

Leandro et al., American College of Rheumatology Conference 2025 Abstract #2458

Five patients (83.3%) achieved DORIS with median onset of 5.1 months

50 million cell dose patient cohort (n=6)



- Responses ongoing with no flare as of last follow-up
- Median onset of DORIS remission: 5.1 months (range: 4.9 – 8.9)
- No patient received any immunosuppressive therapy after obe-cel
- By month 6, all patients tapered the steroid dose to ≤5 mg/day

Leandro et al., American College of Rheumatology Conference 2025 Abstract #2458

DORIS (Definition of Remission in SLE) Irrespective of serology; may be on antimalarials, low dose steroids (prednisolone ≤ 5mg/day): SLEDAI-2K = 0 and PGA < 0.5 on a visual analog scale from 0-3.

Upcoming data presentations highlight pipeline opportunities

ASH 2025 Annual Meeting Preview

Oncology

- **Pediatric ALL**
  Poster: Treatment of pediatric pts with R/R B-ALL with obe-cel: preliminary findings from Phase Ib/II CATULUS trial
- **Adult ALL**
  Oral: Impact of CAR product cell phenotypes on clinical outcomes following treatment with obe-cel from FELIX trial
- **Adult ALL**
  Poster: CAR T cell persistence at Month 3 predicts clinical outcomes in adult patients with r/r B-ALL treated with obecabtagene autoleucel (obe-cel) from FELIX rial

Autoimmune

- **srSLE**
  Oral: Updated Phase I data with longer follow-up from CARLYSLE trial

ROCCA Consortium Independent Analysis

- **Adult ALL**
  Poster: Patient characteristics, toxicity, and response after real world administration of obe-cel and brexu-cel

Financial Results

Financial summary – key metrics*

USD ($' 000)	Q3 2025	Q3 2024	Variance
Total revenue, net	21,194	-	21,194
Cost and operating expenses:			
Cost of sales	(28,643)	-	(28,643)
Research and development expenses, net	(27,892)	(40,323)	12,431
Selling, general and administrative expenses	(36,280)	(27,330)	(8,950)
Loss on disposal of property and equipment	-	(223)	223
Loss from operations	**(71,621)**	**(67,876)**	**(3,745)**
Total comprehensive loss	**(84,900)**	**(55,084)**	**(29,816)**

*Select metrics only; for full financials please refer to the Company's 10-Q filing

$367.4M* **as of September 30, 2025**

The Company is well capitalized to drive the launch and commercialization of obe-cel in r/r B-ALL and to generate data in the LN and pALL potential pivotal trials and MS Phase 1 trial

*Cash, cash equivalents and marketable securities

Upcoming news flow

Upcoming milestones

Anticipated Milestone or Catalyst	Anticipated Timing
Initial clinical data from CATULUS trial in pediatric ALL	ASH Annual Meeting 2025
Longer-term follow up data from CARLYSLE trial	ASH Annual Meeting 2025
Expect to dose first patient in Phase 2 LUMINA trial in lupus nephritis	By YE 2025
Expect to dose first patient in Phase 1 ALARIC trial in AL amyloidosis (UCL collaboration)	By YE 2025

Obe-cel Oncology | Obe-cel Autoimmune/B cell Mediated Disease

Near-term priorities to build shareholder value & patient benefit

Entering next phase of growth with commercial launch on track

1. Drive market share in aALL
2. Improve margins
3. Expand beyond aALL

Autolus

Thank you